R&D spend climbing faster than revenue, study shows

3 September 2020

A new analysis from professional services firm BDO shows that demands for innovation have caused research and development (R&D) spend to outpace revenue growth from 2016 to 2019.

R&D spending in the life sciences industry surged 22% from 2018 to 2019, while revenues increased just 2%, continuing the pattern of recent years.

"Sharing information across and beyond traditional boundaries is no longer a nice-to-have. It’s a must-have"Looking ahead, BDO predicts that this trend is likely to continue amid pricing pressures, shifting reimbursement models, looming patent expirations and creative partnerships formed amid the pandemic.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK